How a UK drug development program and a rare regulatory license became the first prefilled NAD+ injector pen in the United States.
NAD+ (nicotinamide adenine dinucleotide) is a central metabolic cofactor involved in mitochondrial energy production and DNA repair. Tissue NAD+ levels decline with age, and clinical interest in replenishing NAD+ has grown substantially over the past decade.
Traditional options leave major gaps for practices and patients. IV NAD+ infusions require long chair time and high visit costs. Oral precursors rely on enzymatic conversion and first-pass metabolism. Vial-and-syringe kits place the burden of preparation and dosing on the patient.
Physicians needed a ready-to-use, precisely dosed, subcutaneous product with consistent quality and practical at-home administration.
SpectrumX, based in the United Kingdom, invested in a full drug development program to create a NAD+ formulation with exceptional stability, potency, and purity. This program produced a prefilled subcutaneous injector pen delivering 1,000 mg of NAD+ as a 30-day supply with adjustable dosing (1 unit = 3.33 mg NAD+).
SpectrumX holds a Medical Specials license in the UK, a rare regulatory designation that requires rigorous manufacturing quality, testing, and documentation standards.
Medivive is SpectrumX's exclusive US commercialization partner. Bringing the formulation to the US required a formal technology transfer, a compliant manufacturing and dispensing supply chain, and a physician-facing prescribing platform.
Technology Transfer and Manufacturing: Through a formal transfer led by Medivive, the SpectrumX formulation was transferred to VeV Scientific, an FDA-registered 503B outsourcing facility in San Diego operating under cGMP standards.
Dispensing and Fulfillment: The finished pen is dispensed by Chemistry Rx, a licensed 503A pharmacy with PCAB accreditation and LegitScript certification. Cold-chain shipping is sent directly to patients in 41 states.
The Medivive Platform: Medivive facilitates credentialing and prescribing for licensed clinicians. Physicians prescribe in under 2 minutes. Chemistry Rx dispenses and fulfills each patient-specific prescription.
Drug development program and Medical Specials license framework.
Formal tech transfer and cGMP 503B manufacturing.
503A dispensing, cold-chain fulfillment, 41-state footprint.
The Medivive supply chain operates within the DQSA and Section 503B framework. The arrangement supports compliant distribution from a 503B outsourcing facility to a state-licensed pharmacy for patient-specific dispensing. A formal legal opinion letter from outside counsel is available to physicians upon request.
NAD+ is a coenzyme present in every living cell and is central to energy metabolism, DNA repair pathways, and cellular stress response. Published literature has documented age-associated declines in tissue NAD+ levels and ongoing clinical interest in restoration strategies.
Subcutaneous delivery bypasses first-pass metabolism and can support practical, consistent administration in outpatient use. For references, visit the FAQ references section.
Contact us at clyde@medivive.com or schedule a call.